Ongaro Marie, Spahr Laurent, Giostra Emiliano, Negro Francesco
Services de gastroentérologie et hépatologie et de pathologie clinique, HUG, 1211 Genève 14.
Rev Med Suisse. 2020 Sep 2;16(704):1538-1543.
Hepatitis D virus causes chronic hepatitis D. The virus is defective, meaning it requires simultaneous presence of hepatitis B virus within the hepatocytes to complete its viral cycle. Globally, 15 to 20 millions people are estimated to be chronically co-infected by hepatitis B and D viruses. Current therapy remains limited to pegylated interferon alfa, which has an unsatisfactory success rate, several contraindications and many side effects. Drugs directly targeting the hepatitis D virus life cycle are being developed with promising results. These drugs target viral entry into hepatocytes, virion assembly or secretion from infected hepatocytes. This article provides an overview of the newly developed therapies and their efficacy.
丁型肝炎病毒可引发慢性丁型肝炎。该病毒具有缺陷性，也就是说它需要在肝细胞内同时存在乙型肝炎病毒才能完成其病毒周期。据估计，全球有1500万至2000万人同时受到乙型和丁型肝炎病毒的慢性感染。目前的治疗方法仍局限于聚乙二醇化干扰素α，其成功率不尽人意，存在多种禁忌症和许多副作用。正在研发直接针对丁型肝炎病毒生命周期的药物，且已取得了有前景的成果。这些药物作用于病毒进入肝细胞的过程、病毒粒子的组装或从受感染肝细胞的分泌过程。本文概述了新研发的治疗方法及其疗效。
